How the Rest of the World’s Capacity-Building Impacts the Global Regulatory Dossier
This article was originally published in The Gold Sheet
Executive Summary
Emerging nations are supplanting the developed world’s vision of global pharmaceutical regulatory harmonization with one of their own: capacity-building and convergence. A main point of focus will be creating the regulatory review and manufacturing capability needed to launch biosimilars in countries like Brazil and Taiwan.